Gene:
CYP2C9
cytochrome P450, family 2, subfamily C, polypeptide 9

Available Prescribing Info

Dosing Guidelines
  1. Annotation of CPIC Guideline for phenytoin and CYP2C9,HLA-B
  2. Annotation of CPIC Guideline for warfarin and CYP2C9,CYP4F2,VKORC1
  3. Annotation of DPWG Guideline for acenocoumarol and CYP2C9
  4. Annotation of DPWG Guideline for glibenclamide and CYP2C9
  5. Annotation of DPWG Guideline for gliclazide and CYP2C9
  6. Annotation of DPWG Guideline for glimepiride and CYP2C9
  7. Annotation of DPWG Guideline for phenprocoumon and CYP2C9
  8. Annotation of DPWG Guideline for phenytoin and CYP2C9
  9. Annotation of DPWG Guideline for tolbutamide and CYP2C9
last updated 03/15/2017

1. Annotation of CPIC Guideline for phenytoin and CYP2C9,HLA-B

Summary

Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Additionally, patients with the CYP2C9 poor metabolizer phenotype may require reduced doses of phenytoin.

There's more of this guideline. Read more.


last updated 02/08/2017

2. Annotation of CPIC Guideline for warfarin and CYP2C9,CYP4F2,VKORC1

Summary

The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium. The recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823.

There's more of this guideline. Read more.










Annotated Labels

  1. Annotation of FDA Label for celecoxib and CYP2C9
  2. Annotation of FDA Label for enzalutamide and CYP2C19,CYP2C8,CYP2C9,CYP3A4
  3. Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6
  4. Annotation of FDA Label for flurbiprofen and CYP2C9
  5. Annotation of FDA Label for lesinurad and CYP2C9
  6. Annotation of FDA Label for marinol and CYP2C9
  7. Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B
  8. Annotation of FDA Label for piroxicam and CYP2C9
  9. Annotation of FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5
  10. Annotation of FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1
  11. Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4
  12. Annotation of PMDA Label for celecoxib and CYP2C9
  13. Annotation of HCSC Label for celecoxib and CYP2C9
  14. Annotation of HCSC Label for warfarin and CYP2C9,VKORC1

last updated 10/25/2013

1. Annotation of FDA Label for celecoxib and CYP2C9

Actionable PGx

Summary

Celecoxib is metabolized primarily by CYP2C9. Patients who are known or suspected to be poor CYP2C9 metabolizers should be administered celecoxib with caution. Consider a dose reduction by 50% (or alternative management for juvenile rheumatoid arthritis (JRA)) in patients who are known or suspected to be CYP2C9 poor metabolizers.

There's more of this label. Read more.



last updated 03/15/2017

3. Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6

Actionable PGx

Summary

The FDA-approved drug label for flibanserin (ADDYI) states that poor metabolizers of CYP2C19 had increased exposure to the drug as compared to extensive metabolizers. One subject who was a poor metabolizer experienced syncope. The label also notes the influence of CYP2D6 and CYP2C9 on flibanserin exposure.

There's more of this label. Read more.


last updated 10/25/2013

4. Annotation of FDA Label for flurbiprofen and CYP2C9

Informative PGx

Summary

In vitro studies have demonstrated that cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen. CYP2C9 poor metabolizers should be administered flurbiprofen with caution due to the possibility of high plasma levels resulting from decreased clearance.

There's more of this label. Read more.




last updated 10/25/2013

7. Annotation of FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B

Actionable PGx

Summary

A strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLAB*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.

There's more of this label. Read more.


8. Annotation of FDA Label for piroxicam and CYP2C9

Actionable PGx

Summary

The FDA-approved drug label for piroxicam (FELDENE) states that CYP2C9 intermediate and poor metabolizers had higher systemic levels of piroxicam as compared to normal metabolizers, and that known or suspected CYP2C9 poor metabolizers should consider a dose reduction.

There's more of this label. Read more.



last updated 07/14/2014

10. Annotation of FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1

Actionable PGx

Summary

Warfarin (Coumadin) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillationa and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration.

There's more of this label. Read more.


last updated 08/06/2014

11. Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

There's more of this label. Read more.


12. Annotation of PMDA Label for celecoxib and CYP2C9

Actionable PGx

Summary

The PMDA package insert for celecoxib (Celecox) notes that individuals with the CYP2C9 *1/*3 or *3/*3 genotypes had increased AUC or Cmax of celecoxib as compared to those with the *1/*1 genotype.

There's more of this label. Read more.


13. Annotation of HCSC Label for celecoxib and CYP2C9

Actionable PGx

Summary

The product monograph for celecoxib (CELEBREX) notes that patients who are CYP2C9 poor metabolizers should be administered celecoxib with caution. It further states that the drug should be introduced at half the lowest recommended dose in these individuals, with a maximum recommended dose of 100 mg/day. However, the product monograph does not discuss CYP2C9 genotyping prior to treatment.

There's more of this label. Read more.


14. Annotation of HCSC Label for warfarin and CYP2C9,VKORC1

Actionable PGx

Summary

The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the VKORC1 gene, such as -1639G>A, are also associated with changes in the dose requirement of warfarin.

There's more of this label. Read more.


Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below. Please follow the link in the "Position" column for more information about a particular variant. Each link in the "Position" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for CYP2C9

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *1 N/A N/A N/A
No VIP available CA VA *2 N/A N/A N/A
No VIP available CA VA *3 N/A N/A N/A
No VIP available No VIP available VA *4 N/A N/A N/A
No VIP available CA VA *5 N/A N/A N/A
No VIP available CA VA *6 N/A N/A N/A
No VIP available CA VA *8 N/A N/A N/A
No VIP available No VIP available VA *9 N/A N/A N/A
No VIP available No VIP available VA *10 N/A N/A N/A
No VIP available CA VA *11 N/A N/A N/A
No VIP available No VIP available VA *12 N/A N/A N/A
No VIP available CA VA *13 N/A N/A N/A
No VIP available No VIP available VA *14 N/A N/A N/A
No VIP available No VIP available VA *17 N/A N/A N/A
No VIP available No VIP available VA *25 N/A N/A N/A
No VIP available No VIP available VA *30 N/A N/A N/A
No VIP available No VIP available VA *31 N/A N/A N/A
No VIP available No VIP available VA *32 N/A N/A N/A
No VIP available No VIP available VA *33 N/A N/A N/A
No VIP available No VIP available VA *57 N/A N/A N/A
No VIP available No VIP available VA *58 N/A N/A N/A
No VIP available CA VA *59 N/A N/A N/A
No VIP available CA VA
rs10509680 NC_000010.10:g.96734339G>T, NC_000010.11:g.94974582G>T, NG_008385.1:g.40925G>T, NM_000771.3:c.961+2337G>T, XM_005269575.1:c.961+2337G>T, rs45630770, rs45631363
G > T
SNP
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
No VIP available CA VA
rs12782374 NC_000010.10:g.96695351G>A, NC_000010.11:g.94935594G>A, NG_008385.1:g.1937G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs141011391 NC_000010.10:g.96748733A>G, NC_000010.11:g.94988976A>G, NG_008385.1:g.55319A>G, NM_000771.3:c.1421A>G, NP_000762.2:p.Asn474Ser, XM_005269575.1:c.1275-490A>G
A > G
SNP
N474S
rs1799853 NC_000010.10:g.96702047C=, NC_000010.10:g.96702047C>T, NC_000010.11:g.94942290C=, NC_000010.11:g.94942290C>T, NG_008385.1:g.8633C=, NG_008385.1:g.8633C>T, NM_000771.3:c.430C=, NM_000771.3:c.430C>T, NP_000762.2:p.Arg144=, NP_000762.2:p.Arg144Cys, XM_005269575.1:c.430C=, XM_005269575.1:c.430C>T, XP_005269632.1:p.Arg144=, XP_005269632.1:p.Arg144Cys, rs17110268, rs28371674, rs33968134, rs60690363
C > T
SNP
R144C
No VIP available CA VA
rs1934969 NC_000010.10:g.96748495A>T, NC_000010.11:g.94988738A>T, NG_008385.1:g.55081A>T, NM_000771.3:c.1292-109A>T, XM_005269575.1:c.1275-728A>T, rs17522303, rs59299689
A > T
SNP
No VIP available CA VA
rs28371685 NC_000010.10:g.96740981C>T, NC_000010.11:g.94981224C>T, NG_008385.1:g.47567C>T, NM_000771.3:c.1003C>T, NP_000762.2:p.Arg335Trp, XM_005269575.1:c.1003C>T, XP_005269632.1:p.Arg335Trp, rs60219528
C > T
SNP
R335W
No VIP available CA VA
rs28371686 NC_000010.10:g.96741058C>G, NC_000010.11:g.94981301C>G, NG_008385.1:g.47644C>G, NM_000771.3:c.1080C>G, NP_000762.2:p.Asp360Glu, XM_005269575.1:c.1080C>G, XP_005269632.1:p.Asp360Glu, rs57527516
C > G
SNP
D360E
No VIP available No Clinical Annotations available VA
rs2860905 NC_000010.10:g.96702295G>A, NC_000010.11:g.94942538G>A, NG_008385.1:g.8881G>A, NM_000771.3:c.481+197G>A, XM_005269575.1:c.481+197G>A, rs56268370
G > A
SNP
No VIP available CA VA
rs4086116 NC_000010.10:g.96707202C>T, NC_000010.11:g.94947445C>T, NG_008385.1:g.13788C>T, NM_000771.3:c.482-334C>T, XM_005269575.1:c.482-334C>T, rs56627368, rs57822479
C > T
SNP
No VIP available CA VA
rs4917639 NC_000010.10:g.96725535A>C, NC_000010.11:g.94965778A>C, NG_008385.1:g.32121A>C, NM_000771.3:c.820-6326A>C, XM_005269575.1:c.820-6326A>C, rs17429632, rs56870279
A > C
SNP
No VIP available CA VA
rs4918758 NC_000010.10:g.96697252T>C, NC_000010.11:g.94937495T>C, NG_008385.1:g.3838T>C, NM_000771.3:c.-1188T>C, XM_005269575.1:c.-1188T>C, rs17110346
T > C
SNP
No VIP available CA VA
rs56165452 NC_000010.10:g.96741054T>C, NC_000010.11:g.94981297T>C, NG_008385.1:g.47640T>C, NM_000771.3:c.1076T>C, NP_000762.2:p.Ile359Thr, XM_005269575.1:c.1076T>C, XP_005269632.1:p.Ile359Thr
T > C
SNP
I359T
No VIP available CA VA
rs7089580 NC_000010.10:g.96705223A>T, NC_000010.11:g.94945466A>T, NG_008385.1:g.11809A>T, NM_000771.3:c.482-2313A>T, XM_005269575.1:c.482-2313A>T, rs111172059, rs58626010
A > T
SNP
No VIP available CA VA
rs71486745 NC_000010.10:g.96695776_96695777delGT, NC_000010.11:g.94936019_94936020delGT, NG_008385.1:g.2362_2363delGT
GT > -
indel
No VIP available CA VA
rs72558187 NC_000010.10:g.96701715T>C, NC_000010.11:g.94941958T>C, NG_008385.1:g.8301T>C, NM_000771.3:c.269T>C, NP_000762.2:p.Leu90Pro, XM_005269575.1:c.269T>C, XP_005269632.1:p.Leu90Pro, rs74052158
T > C
SNP
L90P
No VIP available No Clinical Annotations available VA
rs72558189 NC_000010.10:g.96701991G>A, NC_000010.11:g.94942234G>A, NG_008385.1:g.8577G>A, NM_000771.3:c.374G>A, NP_000762.2:p.Arg125His, XM_005269575.1:c.374G>A, XP_005269632.1:p.Arg125His, rs73994288
G > A
SNP
R125H
No VIP available CA VA
rs7900194 NC_000010.10:g.96702066G>A, NC_000010.11:g.94942309G>A, NG_008385.1:g.8652G>A, NM_000771.3:c.449G>A, NP_000762.2:p.Arg150His, XM_005269575.1:c.449G>A, XP_005269632.1:p.Arg150His, rs57530584
G > A
SNP
R150H
No VIP available No Clinical Annotations available VA
rs9332092
T > C
SNP
No VIP available No Clinical Annotations available VA
rs9332094 NC_000010.10:g.96696674T>C, NC_000010.11:g.94936917T>C, NG_008385.1:g.3260T>C, NM_000771.3:c.-1766T>C, XM_005269575.1:c.-1766T>C, rs61444591
T > C
SNP
No VIP available CA VA
rs9332096 NC_000010.10:g.96696875C>T, NC_000010.11:g.94937118C>T, NG_008385.1:g.3461C>T, NM_000771.3:c.-1565C>T, XM_005269575.1:c.-1565C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs9332098
G > A
SNP
No VIP available No Clinical Annotations available VA
rs9332104 NC_000010.10:g.96698690T>C, NC_000010.11:g.94938933T>C, NG_008385.1:g.5276T>C, NM_000771.3:c.168+83T>C, XM_005269575.1:c.168+83T>C, rs58097354
T > C
SNP
No VIP available No Clinical Annotations available VA
rs9332120 NC_000010.10:g.96701850T>C, NC_000010.11:g.94942093T>C, NG_008385.1:g.8436T>C, NM_000771.3:c.331+73T>C, XM_005269575.1:c.331+73T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs9332127 NC_000010.10:g.96707471G>C, NC_000010.11:g.94947714G>C, NG_008385.1:g.14057G>C, NM_000771.3:c.482-65G>C, XM_005269575.1:c.482-65G>C, rs17847038, rs58304507
G > C
SNP
No VIP available CA VA
rs9332131 NC_000010.10:g.96709039delA, NC_000010.11:g.94949282delA, NG_008385.1:g.15625delA, NM_000771.3:c.817delA, NP_000762.2:p.Lys273Argfs, XM_005269575.1:c.817delA, XP_005269632.1:p.Lys273Argfs
A > -
indel
K273R
No VIP available No Clinical Annotations available VA
rs9332174 NC_000010.10:g.96732097A>G, NC_000010.11:g.94972340A>G, NG_008385.1:g.38683A>G, NM_000771.3:c.961+95A>G, XM_005269575.1:c.961+95A>G, rs17521927, rs60502756
A > G
SNP
No VIP available No Clinical Annotations available VA
rs9332197 NC_000010.10:g.96740908T>C, NC_000010.11:g.94981151T>C, NG_008385.1:g.47494T>C, NM_000771.3:c.962-32T>C, XM_005269575.1:c.962-32T>C, rs60905497
T > C
SNP
No VIP available No Clinical Annotations available VA
rs9332238 NC_000010.10:g.96748492G>A, NC_000010.11:g.94988735G>A, NG_008385.1:g.55078G>A, NM_000771.3:c.1292-112G>A, XM_005269575.1:c.1275-731G>A
G > A
SNP
No VIP available CA VA
rs9332239 NC_000010.10:g.96748777C>T, NC_000010.11:g.94989020C>T, NG_008385.1:g.55363C>T, NM_000771.3:c.1465C>T, NP_000762.2:p.Pro489Ser, XM_005269575.1:c.1275-446C>T, rs59029001
C > T
SNP
P489S
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  CYP2C10
Alternate Symbols:  P450IIC9
PharmGKB Accession Id: PA126

Details

Cytogenetic Location: chr10 : q23.33 - q23.33
GP mRNA Boundary: chr10 : 96698350 - 96749486
GP Gene Boundary: chr10 : 96688350 - 96752486
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

CYP2C9 is a phase I drug-metabolizing cytochrome P450 (CYP450) enzyme isoform that plays a major role in the oxidation of both xenobiotic and endogenous compounds. Gray et al. [Article:8530044] identified CYP2C9 as one of several CYP2C genes clustered in a 500kb region on chromosome 10q24. The cluster comprises four genes arranged in the order CYP2C8-CYP2C9-CYP2C19-CYP2C18 [Article:8530044]. Several studies identified a single nucleotide polymorphism (SNP) linkage between the CYP2C8 and CYP2C9 genes [Articles:8530044, 12435384, 19381162]. CYP2C9 is primarily expressed in the liver, and the expression level is reported to be the second highest among CYP isoforms [Article:12580989]. Only the CYP enzyme CYP3A4 is quantitatively more highly expressed in human liver [Article:15822186]. It has been estimated that CYP2C9 is responsible for the metabolic clearance of up to 15%-20% of all drugs undergoing Phase I metabolism [Articles:19152219, 11927841].

Inducer and Inhibitors: CYP2C9 is induced by rifampicin [Article:19369937]. Treatment with rifampicin has been shown consistently to increase the clearance of drugs eliminated by CYP2C9. The clearance of losartan, phenytoin, tolbutamide and S-warfarin is approximately doubled in healthy volunteers or patients treated with rifampicin [Articles:9663807, 18650803]. CYP2C9 is inhibited by amiodarone, fluconazole, and sulphaphenazole among other drugs [Article:9663807]. Dangerous drug-drug interaction can arise when an inhibitor such as one of these is added to a therapeutic regime that include drugs with a low therapeutic index, such as S-warfarin, tolbutamine, and phenytoin [Articles:7944078, 8806399, 15963007]. For example, there are numerous studies documenting potentiation of the anticoagulant effect of warfarin in patients coadministered with amiodarone [Articles:18463344, 14677664, 1563209].

Structure: CYP2C9 is the enzyme responsible for the metabolism of the S-isomer of warfarin that is principally responsible for the anticoagulant effect of the drug. The crystal structure of human CYP2C9 was described by Williams et al. [Article:12861225], for both CYP2C9 in complex with warfarin and unliganded CYP2C9 (Protein Data Bank ID: 1OG2 and 1OG5, respectively). The structure showed unanticipated interactions between CYP2C9 and warfarin, revealing a new binding pocket, suggesting that CYP2C9 may simultaneously accommodate multiple ligands during its biologic function [Article:12861225]. Structural analysis suggested that CYP2C9 may undergo an allosteric change when binding warfarin [Article:12861225]. An X-ray crystal structure of CYP2C9, in complex with the NSAID flurbiprofen, has also been described (Protein Data Bank ID: 1R9O) [Article:15181000].

Genetic phenotypes and adverse drug reactions (ADR): The gene coding for the CYP2C9 enzyme is highly polymorphic, including functional variants of major pharmacogenetic importance. Changes in metabolic activity caused by genetic variants in CYP2C9 play a major role in pathogenesis due to ADRs. Patients with low enzyme activity are at risk of ADR, especially for CYP2C9 substrates with a narrow therapeutic window, such as S-warfarin, phenytoin, glipizide, and tolbutamide [Article:14511900]. A large body of literature investigates two common non-synonymous variants within CYP2C9 (R144C, [rs1799853] and I359L, [rs1057910]), leading to poor metabolism phenotypes. Both variants have significantly lower frequencies in African and Asian populations compared to Caucasian populations [Articles:11927841, 19151603], see frequency tables under Important variants. Individuals with these variants are at risk of prolonged bleeding time and increased incidence of severe bleeding in warfarin therapy [Article:10073515], higher possibility of low blood sugar levels during glipizide and tolbutamide therapy [Article:10208645], and more frequent symptoms of overdose in phenytoin therapy [Article:10774639]. Patients with the poor metabolizer *2 (identified by R144C) and *3 (identified by I359L) haplotypes require lower doses of warfarin to achieve a similar anticoagulant as patients with at least one *1 (wild-type) haplotype [Articles:10073515, 19031075]. However, it is now known that CYP2C9 genotype accounts for only part of the variability in warfarin sensitivity [Articles:11893129, 12621390] because VKORC1 genotype, age, and weight are also key factors in predicting the therapeutic dose for warfarin [Article:16424822]. CYP2C9 is responsible for about 90% of phenytoin metabolism, and the CYP2C9*2 and *3 haplotypes decrease the metabolism of phenytoin [Articles:19258521, 16873909, 11434505].

Besides the two variants mentioned above, a large number of SNPs have been described in the regulatory and coding regions of the CYP2C9 gene (http://www.cypalleles.ki.se/cyp2c9.htm). Some of the polymorphisms are associated with reduced enzyme activity compared to wild-type in in-vitro experiments; only a few enzyme experiments have been done in-vivo. CYP2C9*6 (818delA, rs933213) is a rare (1 allele in 158 African Americans, 0 in Caucasians) null allele with lack of activity due to a splicing mutation that causes a frameshift resulting in a truncated protein [Article:11740344]. The variant I359T (CYP2C*4) is also a rare (0.5% in African Americans, 6% in Caucasians) polymorphism [Articles:8873220, 9631918]. Both have been detected in patients who had adverse reactions to phenytoin [Articles:11740344, 10739176]. CYP2C9*5 (D360E, rs28371683), *6, *8 (R150H, rs7900194) and *11 (R335W, rs28371685) variants were associated with decreased phenytoin metabolism in a black population [Article:16220110]. The CYP2C9 promoter contains important regulatory elements: two HNF4 sites, a nuclear receptor pregnane X receptor binding site, a constitutive androstane receptor (CAR)/PXR site, and a glucocorticoid responsive element [Articles:15919766, 12181452, 11678789]. There have been multiple polymorphisms detected in the 5' untranslated region of CYP2C9 but these have not yet been shown to contribute to response to warfarin [Articles:15900281, 16513444] or phenytoin [Article:11434505] in-vivo, beyond those which appear to be in linkage disequilibrium with known exonic variants [Articles:15900281, 15070684, 11503012]. A recent paper investigating 22 known and 9 novel promoter SNPs with an in-vitro promoter activity assay suggests that genetic variation within CYP2C9 regulatory sequences is likely to contribute to differences in CYP2C9 phenotype, both within and among different populations, independent from known exonic variants [Article:18310303].

Citation Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and genomics. 2010. Van Booven Derek, Marsh Sharon, McLeod Howard, Carrillo Michelle Whirl, Sangkuhl Katrin, Klein Teri E, Altman Russ B. PubMed
History

Submitted by Derek Van Booven (CREATE), Sharon Marsh, Howard McLeod (CREATE), Michelle Whirl Carrillo, Katrin Sangkuhl

Key Publications
  1. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et biophysica acta. 2007. Kirchheiner Julia, Seeringer Angela. PubMed
  2. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical pharmacology and therapeutics. 2005. Kirchheiner Julia, Brockmöller Jürgen. PubMed
  3. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug metabolism and disposition: the biological fate of chemicals. 2005. Rodrigues A David. PubMed
  4. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. European journal of clinical pharmacology. 2003. Griskevicius Laimonas, Yasar Umit, Sandberg Mia, Hidestrand Mats, Eliasson Erik, Tybring Gunnel, Hassan Moustapha, Dahl Marja-Liisa. PubMed
  5. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 2003. Kirchheiner Julia, Störmer Elke, Meisel Christian, Steinbach Nadine, Roots Ivar, Brockmöller Jürgen. PubMed
  6. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA : the journal of the American Medical Association. 2002. Higashi Mitchell K, Veenstra David L, Kondo L Midori, Wittkowsky Ann K, Srinouanprachanh Sengkeo L, Farin Fred M, Rettie Allan E. PubMed
  7. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999. Aithal G P, Day C P, Kesteven P J, Daly A K. PubMed
  8. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British journal of clinical pharmacology. 1998. Miners J O, Birkett D J. PubMed
  9. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995. Gray I C, Nobile C, Muresu R, Ford S, Spurr N K. PubMed
Variant Summaries rs1057910, rs1799853
Haplotype Summaries CYP2C9*2, CYP2C9*3
Drugs
Pathways

Haplotype Overview

Haplotypes in the "CYP2C9 Cytochrome P450 Nomenclature DB Haplotype Set" are derived from the Human Cytochrome P450 (CYP) Allele Nomenclature Database. The Human Cytochrome P450 (CYP) Allele Nomenclature Database states that nucleotide changes listed below are based on NCBI Reference Sequence M61857.1. Note that the nucleotide positions from the Human Cytochrome P450 (CYP) Allele Nomenclature Database do not directly match the given NCBI reference sequence; rather nucleotide base numbering appears to start at position 11 in the sequence file (ATG start codon). For questions about nucleotide positions, please contact the Human Cytochrome P450 (CYP) Allele Nomenclature Database directly, as they are the authoritative source on cytochrome P450 nomenclature.

Haplotypes in the "CPIC CYP2C9 Haplotype Set" are from the CYP2C9 Allele definition table.

Last updated 2/6/17.

Source: PharmGKB

CPIC CYP2C9 Haplotype Set

CYP2C9 Cytochrome P450 Nomenclature DB Haplotype Set

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
    Nateglinide metabolism and transport in liver cell
  1. Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Caffeine Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
  1. Celecoxib Pathway, Pharmacokinetics
    Schematic representation of celecoxib metabolism in human liver cell.
  1. Clopidogrel Pathway, Pharmacokinetics
    Representation of genes involved in metabolism of clopidogrel.
  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
  1. Doxepin Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of the tricyclic doxepin.
  1. Fluoxetine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of fluoxetine.
  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Gefitinib Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the transportation and metabolism of gefitinib.
  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Ifosfamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of ifosfamide.
  1. Losartan Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of losartan.
  1. Nevirapine Pathway, Pharmacokinetics
    Representation of candidate genes involved in biotransformation of nevirapine and its mechanism of action in an infected liver cell.
  1. Pazopanib Pathway, Pharmacokinetics
    Stylized representation of pazopanib transport and metabolism in the liver.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.
  1. Rosiglitazone Pathway, Pharmacokinetics
    Rosiglitazone is transported from hepatic sinusoids into hepatocytes -- a process mediated by the organic anion transporting polypeptide, where is is metabolized by cytochrome p450 2C8 and 2C9.
  1. Sorafenib Pharmacokinetics
    Schematic representation of sorafenib metabolism in human liver cell.
  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
  1. Tamoxifen Pathway, Pharmacokinetics
    Diagram showing candidate genes for tamoxifen metabolism in the liver.
  1. Valproic Acid Pathway, Pharmacokinetics
    Graphic representation of the candidate genes involved in valproic acid pharmacokinetics.
  1. Voriconazole Pathway, Pharmacokinetics
    Pathway describing the metabolism of voriconazole
  1. Warfarin Pathway, Pharmacokinetics
    Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.
  1. Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
    Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
APOE
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP4F2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GGCX
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VKORC1

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
4-hydroxytamoxifen
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abiraterone
DG No Drug Label available CA VA No VIP available No VIP available
acenocoumarol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
anastrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
aspirin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
atenolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
atorvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
belinostat
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
benzbromarone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
bosentan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
brivaracetam
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
busulfan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabozantinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
caffeine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
capecitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
carbamazepine
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
carvedilol
celecoxib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ceritinib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
citalopram
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clobazam
clopidogrel
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
crizotinib
cyclophosphamide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dabrafenib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dasatinib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexlansoprazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dextromethorphan
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
diazepam
diclofenac
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
doxepin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
drospirenone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
efavirenz
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eltrombopag
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
endoxifen
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
enzalutamide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
esomeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ethambutol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethinyl estradiol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flibanserin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluindione
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
fluoxetine
No Dosing Guideline available DL CA VA No VIP available No VIP available
flurbiprofen
fluvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluvoxamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
gefitinib
glibenclamide
DG No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gliclazide
glimepiride
glipizide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gliquidone
ibuprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ifosfamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
imatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
indomethacin
irbesartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
isoniazid
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor / lumacaftor
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lacosamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lamotrigine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lesinurad
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
lornoxicam
losartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
lovastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
marinol
meloxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
methadone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
modafinil
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
n-desmethyltamoxifen
naproxen
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
nateglinide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
nevirapine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
olanzapine
DG No Drug Label available CA VA No VIP available No VIP available
phenprocoumon
phenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
pioglitazone
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
piroxicam
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
prasugrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
primidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
propofol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
pyrazinamide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinidine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
regorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
rifampin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
risperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
rosiglitazone
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
rosuvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rucaparib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ruxolitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
sertraline
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sildenafil
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
simvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
sorafenib
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
sulfamethoxazole
tamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tenoxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
theophylline
tolbutamide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolterodine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimethoprim
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
trimipramine
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
valproic acid
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
venetoclax
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
venlafaxine
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
voriconazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vortioxetine
warfarin
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
zafirlukast
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
zidovudine

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Adenoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Alcoholism
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Anemia, Sickle Cell
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cardiovascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carotid Artery Diseases
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Depressive Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Depressive Disorder, Major
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Diabetes Mellitus
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Diabetes Mellitus, Type 2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
drug reaction with eosinophilia and systemic symptoms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Resistance
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
drug-induced liver injury
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Epidermal Necrolysis, Toxic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Essential hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gastritis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gastrointestinal Hemorrhage
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Heart Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Heart Valve Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
heart valve replacement
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hematoma, Subdural
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
hemoglobin ss disease with vasoocclusive crisis
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
hemopoietic stem cell transplant
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hemorrhage
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hepatitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HIV
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypertension, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypoglycemia
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hypotension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Kidney Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Leukopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Maculopapular Exanthema
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Mental Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
over-anticoagulation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
platelet aggregation
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Psychotic Disorders
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pulmonary Embolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Recurrence
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Rheumatic Heart Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
severe cutaneous adverse reactions
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Stevens-Johnson Syndrome
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thrombosis of cerebral veins
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thyrotoxicosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time above therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time below therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time in therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time to achieve stable dose
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time to therapeutic inr
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tuberculosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Vasculitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
venous thromboembolism
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Venous Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Wegener Granulomatosis

Publications related to CYP2C9: 749

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. European journal of clinical pharmacology. 2017. Wattanachai Nitsupa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts. Clinical pharmacology and therapeutics. 2017. Caraballo Pedro J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. European journal of clinical pharmacology. 2017. Yampayon Kittika, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement. Journal of clinical pharmacy and therapeutics. 2017. Tang X-Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dapsone-induced agranulocytosis - possible involvement of low activity N-acetyltransferase 2. Fundamental & clinical pharmacology. 2017. Potočnjak Ines, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy. Journal of Ayurveda and integrative medicine. 2017. Thaker Saket J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential effects of predictors of warfarin dose according to race/color categories in the admixed Brazilian population. Pharmacogenetics and genomics. 2017. Suarez-Kurtz Guilherme, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial. The primary care companion for CNS disorders. 2017. Olson Marilyn C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Molecular diagnosis & therapy. 2017. Shaul Chanan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. Journal of thrombosis and haemostasis : JTH. 2017. Baranova Ekaterina V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. Journal of thrombosis and haemostasis : JTH. 2017. Hernandez Wenndy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. Medicine. 2017. Liu Rui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of functional CYP2C8, CYP2C9, CYP3A5, and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. Pharmacogenetics and genomics. 2017. Yin Sheng-Ju, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. Pharmacogenomics. 2017. Ragia Georgia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Correlations between the enantio- and regio-selective metabolisms of warfarin. Pharmacogenomics. 2017. Takahashi Harumi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacological reports : PR. 2017. López-García Miguel A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. Journal of thrombosis and haemostasis : JTH. 2016. Zhang Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine. 2016. Misasi Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol. American journal of surgery. 2016. Senagore Anthony J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Archives of pharmacal research. 2016. Kim Se-Hyung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population. Omics : a journal of integrative biology. 2016. De Andrés Fernando, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting prolonged dose titration in patients starting warfarin. Pharmacoepidemiology and drug safety. 2016. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia. Pharmacogenomics. 2016. Mosikian Anna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Theory based PKPD of S- and R-warfarin and effects on INR: influence of body size, composition and genotype in cardiac surgery patients. British journal of clinical pharmacology. 2016. Xue Ling, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico. Pharmacogenomics. 2016. Sánchez-Pozos Katy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets. Pharmacogenomics. 2016. Sivadas Ambily, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Cardiovascular therapeutics. 2016. Zhang Jinhua, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data. European journal of clinical pharmacology. 2016. Smith R L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2016. Brehm Kerstin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. European journal of clinical pharmacology. 2016. Zeng Wu-Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement. Pharmacogenomics. 2016. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016. Eriksson Niclas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR). Toxicology and applied pharmacology. 2016. Pourgholi Leyla, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast. Archives of pharmacal research. 2016. Lee Hyun-Jee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert opinion on drug metabolism & toxicology. 2016. Tverdohleb Tatiana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. Pharmaceutical research. 2016. Gonzalez-Covarrubias Vanessa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2016. Kalpana S R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clinical pharmacology and therapeutics. 2016. Yang Wenjian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2016. Na Gao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2016. Wypasek E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei medical journal. 2016. Cho Sun Mi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin Dosing Algorithms and the Need for Human Intervention. The American journal of medicine. 2016. Kasner Scott E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. Thrombosis and haemostasis. 2016. Shahabi Payman, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of pharmacogenomic VIP variants in Li nationality of southern China. Environmental toxicology and pharmacology. 2016. Ding Yipeng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. Journal of atherosclerosis and thrombosis. 2016. Yi Xingyang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism. Journal of pharmaceutical sciences. 2016. Niwa Toshiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. The Journal of molecular diagnostics : JMD. 2016. Ji Yuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic or -epigenomic biomarkers in drug treatment - two sides of the same medal?. Clinical pharmacology and therapeutics. 2016. Ingelman-Sundberg Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2016. González A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is toxicity of PMMA (paramethoxymethamphetamine) associated with cytochrome P450 pharmacogenetics?. Forensic science international. 2016. Vevelstad Merete, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital. Journal of child and adolescent psychopharmacology. 2016. McGrane Ian R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenetics and genomics. 2016. Tassaneeyakul Wichittra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics. 2016. Schirmer Jan Henrik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. 2016. Shendre Aditi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016. Hocum Brian Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. Anatolian journal of cardiology. 2016. Dilge Taşkın Birce, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. British journal of clinical pharmacology. 2016. Hasunuma Tomoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: A case-control study. Current clinical pharmacology. 2016. Thatte Urmila. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. Pharmacogenomics. 2016. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics. 2016. Shah Rashmi R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. Cardiovascular therapeutics. 2015. An Sook Hee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol. Drug discoveries & therapeutics. 2016. Sehgal Tushar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Tracy Timothy S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome medicine. 2016. Bourgeois Stephane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults. Indian journal of pharmacology. 2016. Sridharan Kannan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2016. Wiley Laura K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PloS one. 2016. Tong Hoi Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PloS one. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. PloS one. 2016. Berm Elizabeth J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Systematic reviews. 2016. Takeuchi Masanobu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2016. Marek Elizabeth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Integrated Patient and Tumor Genetic Testing for Individualized Cancer Therapy. Clinical pharmacology and therapeutics. 2015. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. Thrombosis and haemostasis. 2015. Cerezo-Manchado Juan Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clinical pharmacokinetics. 2015. Gibbons Jacqueline A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. Journal of human genetics. 2015. Jittikoon Jiraphun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management. Clinical and translational science. 2015. Jaja Cheedy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. European journal of clinical pharmacology. 2015. Chung Jee-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. Journal of thrombosis and haemostasis : JTH. 2015. Abohelaika S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics. 2015. Parra Esteban J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Race influences warfarin dose changes associated with genetic factors. Blood. 2015. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. Pharmacogenomics. 2015. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2015. Sermsathanasawadi Nuttawut, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clinic proceedings. 2015. Kaufman Amy L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. The pharmacogenomics journal. 2015. Ortega-Vázquez A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. Archives of medical research. 2015. Šupe Svjetlana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients. British journal of clinical pharmacology. 2015. Lanchote Vera Lucia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59. Drug metabolism and disposition: the biological fate of chemicals. 2015. Dai Da-Peng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy. Pain medicine (Malden, Mass.). 2015. Gupta Anita, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenetics and genomics. 2015. Fohner Alison E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2015. Murto Kimmo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials. Journal of cardiovascular pharmacology. 2015. Wang Zhi-Quan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiology and drug safety. 2015. Roth Joshua A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes. Therapeutic drug monitoring. 2015. Yamamoto Yoshiaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thrombosis research. 2015. Li Xiaoqi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiology and drug safety. 2015. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015. Nagai Rui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of dermatology in pharmacogenomics: drug-induced skin injury. Pharmacogenomics. 2015. Borroni Riccardo G. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Archives of pharmacal research. 2015. Lee Yun-Jeong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. European journal of clinical pharmacology. 2015. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2015. Wypasek Ewa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. International journal of clinical and experimental pathology. 2015. He Yongjun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques. 2015. Jalil Nur Jalinna Abdul, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study. Molecular diagnosis & therapy. 2014. de Oliveira Almeida Vanessa Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ibuprofen pathways. Pharmacogenetics and genomics. 2014. Mazaleuskaya Liudmila L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenetics and genomics. 2014. Drozda Katarzyna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics. 2015. Li Xi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014. Kawai Vivian K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events. Pharmacogenomics. 2015. Karaca Sefayet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics. 2015. Roberts Rebecca L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics. 2015. Sosa-Macias Martha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015. You Joyce H S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients. Pharmacogenomics. 2015. Peng Qi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. PloS one. 2015. Pengo Vittorio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database. PloS one. 2015. Liu Rong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Warfarin dosage response related pharmacogenetics in chinese population. PloS one. 2015. Li Siyue, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Translational research : the journal of laboratory and clinical medicine. 2014. Hernandez Wenndy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: it matters if you're black or white. Blood. 2014. Wadelius Mia. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. European journal of clinical pharmacology. 2014. Snyder Ben D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis. Journal of Korean medical science. 2014. Lee Ji Eun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. Journal of clinical pharmacology. 2014. Li Xi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH. 2014. Franchini M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. Puerto Rico health sciences journal. 2014. Valentín Isa I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics role in the safety of acenocoumarol therapy. Thrombosis and haemostasis. 2014. Jiménez-Varo E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics. Trends in cardiovascular medicine. 2014. Johnson Julie A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Clinical pharmacology and therapeutics. 2014. Caudle Kelly E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA : the journal of the American Medical Association. 2014. Chung Wen-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. Journal of clinical pharmacology. 2014. Robertson Sarah M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenetics and genomics. 2014. Jiménez-Varo Enrique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers. Pharmacogenomics. 2014. Dorado Pedro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Characterizing variability in warfarin dose requirements in children using modelling and simulation. British journal of clinical pharmacology. 2014. Hamberg Anna-Karin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacogenomics. 2014. Giri Anil K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. The pharmacogenomics journal. 2014. Jeong E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. The pharmacogenomics journal. 2014. Hawcutt D B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: A potential role of CYP4F2 and GGCX polymorphisms. Thrombosis research. 2014. Wypasek Ewa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. British journal of haematology. 2014. Vear Susan I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity. Clinical pharmacology and therapeutics. 2014. Roustit M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. Journal of clinical pharmacy and therapeutics. 2014. An S H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An atlas of genetic influences on human blood metabolites. Nature genetics. 2014. Shin So-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatric blood & cancer. 2014. Shaw Kaitlyn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. Pharmacogenomics. 2014. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014. Mizzi Clint, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics, Plasma Concentrations, Clinical Signs and EEG during Propofol Treatment. Basic & clinical pharmacology & toxicology. 2014. Khan Muhammad Suleman, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014. Cerezo-Manchado Juan Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics. 2014. Lee Yee Ming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis. Thrombosis research. 2014. De Tanima, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. Basic & clinical pharmacology & toxicology. 2014. Botton Mariana R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics of platelet inhibitor treatment. British journal of clinical pharmacology. 2014. Trenk Dietmar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. British journal of clinical pharmacology. 2014. Verhoef Talitha I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circulation. Cardiovascular genetics. 2014. Cresci Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clinical pharmacology and therapeutics. 2014. Dotson W D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European journal of clinical pharmacology. 2014. Klen Jasna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. Pharmacological reports : PR. 2014. Nahar Risha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project". American journal of medical genetics. Part C, Seminars in medical genetics. 2014. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. British journal of clinical pharmacology. 2014. Ke Alice Ban, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers. Clinical pharmacology and therapeutics. 2014. Markert C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clinical pharmacology and therapeutics. 2014. Perera M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method. European journal of clinical pharmacology. 2014. Isma'eel Hussain A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. The pharmacogenomics journal. 2014. Gassó P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacoepidemiologic and in Vitro Evaluation of Potential Drug-Drug Interactions of Sulfonylureas with Fibrates and Statins. British journal of clinical pharmacology. 2014. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting. Clinical pharmacology and therapeutics. 2014. Roth Joshua A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2014. Lowenberg Daniella, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenetics and genomics. 2014. Lee Hye-In, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based warfarin dosing in children. Pharmacogenomics. 2014. Hamberg Anna-Karin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. European journal of clinical pharmacology. 2014. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. Pharmacogenomics. 2014. Grossi Enzo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2C9*2 With Bosentan-Induced Liver Injury. Clinical pharmacology and therapeutics. 2013. Markova S M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genetic testing and molecular biomarkers. 2013. Liang Yundan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin. Indian journal of pharmacology. 2014. Karnik Niteen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient. Journal of pharmacological sciences. 2014. Luo Shun-Bin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. Medicina (Kaunas, Lithuania). 2014. Latkovskis Gustavs, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A pharmacogenetics-based warfarin maintenance dosing algorithm from northern chinese patients. PloS one. 2014. Chen Jinxing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of the Superoxide Dismutase 2 Val16Ala Polymorphism on the Relationship between Valproic Acid Exposure and Elevation of gamma-Glutamyltransferase in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis. PloS one. 2014. Ogusu Naoki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Verification of pharmacogenetics-based warfarin dosing algorithms in han-chinese patients undertaking mechanic heart valve replacement. PloS one. 2014. Zhao Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clinical pharmacology and therapeutics. 2013. Van Driest Sara L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An acenocoumarol dose algorithm based on a South-Eastern European population. European journal of clinical pharmacology. 2013. Pop Tudor Radu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC. Cardiovascular interventions. 2013. Viviani Anselmi Chiara, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. Pharmacogenetics and genomics. 2013. Wolkanin-Bartnik Jolanta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnancy and pharmacogenomics in the context of drug metabolism and response. Pharmacogenomics. 2013. Helldén Anders, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. The New England journal of medicine. 2013. Kimmel Stephen E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. The New England journal of medicine. 2013. Verhoef Talitha I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Randomized Trial of Genotype-Guided Dosing of Warfarin. The New England journal of medicine. 2013. Pirmohamed Munir, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. European journal of clinical pharmacology. 2013. Tan Sheng-Lan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. International journal of cardiology. 2013. Yang Jie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 2013. Jonas Daniel E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. The pharmacogenomics journal. 2013. Uppugunduri C R S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. Vascular medicine (London, England). 2013. Kadian-Dodov Daniella L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele. Clinica chimica acta; international journal of clinical chemistry. 2013. O'Brien Travis J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
PS3-4: Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting. Clinical medicine & research. 2013. Roth Joshua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. The pharmacogenomics journal. 2013. Hernandez W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2013. Brehm Kerstin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. Journal of clinical pharmacology. 2013. Prieto-Pérez Rocío, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013. Lee Hon-Kit, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. The pharmacogenomics journal. 2013. Llerena A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. European journal of clinical pharmacology. 2013. Yiannakopoulou Eugenia. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population. European journal of pharmacology. 2013. Gaikwad Tejasvita, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenetics and genomics. 2013. Fohner Alison, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Implication of novel CYP2C9*57 (p.Asn204His) variant in coumarin hypersensitivity. Thrombosis research. 2013. Nahar Risha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage. European journal of clinical pharmacology. 2013. Wang Lian Sheng, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Human psychopharmacology. 2013. Cabaleiro Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. Pharmacogenomics. 2013. Gschwind Liliane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. European journal of clinical pharmacology. 2013. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatric cardiology. 2013. Nguyen Nguyenvu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thrombosis research. 2013. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population. Basic & clinical pharmacology & toxicology. 2013. Ozer Mahmut, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood cells, molecules & diseases. 2013. Buzoianu Anca Dana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?. Current opinion in cardiology. 2013. Shahin Mohamed H A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. European journal of clinical pharmacology. 2013. Cheng Yu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. European journal of clinical pharmacology. 2013. Rusdiana T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Delayed warfarin induced skin necrosis in a patient with poor warfarin metabolizing activity due to interrupted warfarin therapy. European journal of clinical pharmacology. 2013. Gaikwad Tejasvita, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example. Journal of pharmaceutical sciences. 2013. Sadee Wolfgang. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. 2013. Ucar Mahmut, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2013. Ghodke-Puranik Yogita, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. The pharmacogenomics journal. 2013. Dai D-P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thrombosis research. 2013. Skov Jane, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amlodipine - Not a Significant Contributor to Clopidogrel Non-Response?. Heart (British Cardiac Society). 2013. Kreutz Rolf P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenetics and genomics. 2013. Cavallari Larisa H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics. 2013. Hassan Moustapha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G The Indian journal of medical research. 2013. Kaur Anupriya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. The pharmacogenomics journal. 2013. Sosa-Macías M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC genomics. 2013. Daneshjou Roxana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes. Cardiology. 2013. Tomek Aleš, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients. Drug metabolism and pharmacokinetics. 2013. Hirai Keita, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 2012. Sharma Anant, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. International journal of hematology. 2012. Ma Cong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. Journal of thrombosis and haemostasis : JTH. 2012. Verhoef T I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children. Journal of thrombosis and haemostasis : JTH. 2012. Biss T T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012. Ramos Alga S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacological reviews. 2013. Johnson Julie A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Warfarin anticoagulant therapy: a southern Italy pharmacogenetics-based dosing model. PloS one. 2013. Mazzaccara Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in clinical practice and drug development. Nature biotechnology. 2012. Harper Andrew R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenetics and genomics. 2012. Hu Lei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications. Bulletin of experimental biology and medicine. 2012. Sychev D V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. European journal of clinical pharmacology. 2012. Pedersen Rasmus Steen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. Journal of clinical pharmacy and therapeutics. 2012. Smires F Z, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. Journal of human genetics. 2012. Pathare Anil, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates. Pharmacogenetics and genomics. 2012. Pimenoff Ville N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. International journal of clinical pharmacology and therapeutics. 2012. Bae Jung-Woo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenetics and genomics. 2012. Wu Hongyi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. European journal of clinical pharmacology. 2012. Cini Michela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. Pharmacogenomics. 2012. Chan Sze Ling, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics. 2012. van Schie Rianne Mf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. British journal of haematology. 2012. Lund Kirstin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes. European journal of clinical pharmacology. 2012. Hatta Fazleen H M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. Journal of thrombosis and thrombolysis. 2012. Liang Ruijuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects. European journal of drug metabolism and pharmacokinetics. 2012. Allabi Aurel Constant, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: phenytoin pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics. 2012. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Therapeutic drug monitoring. 2012. Lee Kyung-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thrombosis and haemostasis. 2012. Wei Meng, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics. 2012. Andersson Marine L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. The pharmacogenomics journal. 2012. Dorado P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clinical pharmacology and therapeutics. 2012. Liu Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. Journal of the American Heart Association. 2012. Musunuru Kiran, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. Journal of thrombosis and haemostasis : JTH. 2012. Verhoef T I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. The pharmacogenomics journal. 2012. Martis S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thrombosis research. 2012. Kassimis George, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. British journal of clinical pharmacology. 2012. Lacut Karine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing: CoumaGen-II. Circulation. 2012. Anderson Jeffrey L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. Antimicrobial agents and chemotherapy. 2012. Kagaya Hideaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics. 2012. Ramirez Andrea H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. The Annals of pharmacotherapy. 2012. Valentin Isa Ivette, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012. Biss Tina T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012. Moreau Caroline, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. British journal of clinical pharmacology. 2012. Lane Steven, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: caffeine pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Validation of warfarin pharmacogenetic algorithms in clinical practice. Pharmacogenomics. 2012. Marin-Leblanc Mélina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?. Indian heart journal. 2012. Singh Mukesh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU. Pharmacogenomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics. 2011. Dandara Collet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in spanish patients with thromboembolic disease. PloS one. 2012. Borobia Alberto M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PloS one. 2012. Rathore Saurabh Singh, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype. Clinica chimica acta; international journal of clinical chemistry. 2011. Kwon Min-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients. European journal of clinical pharmacology. 2011. Shrif Nassr Eldin M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of Coumarin Dosing: Prevalence of CYP2C9 and VKORC1 Polymorphisms in the Lebanese Population. Genetic testing and molecular biomarkers. 2011. Djaffar-Jureidini Isabelle, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clinical therapeutics. 2011. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. Journal of clinical pharmacology. 2011. Esmerian Maria O, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. British journal of clinical pharmacology. 2011. Botton Mariana Rodrigues, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A. Chinese medical journal. 2011. Gao Lei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. Chirality. 2011. Lu Wenjie Jessie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical pharmacology and therapeutics. 2011. Johnson J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6 and 2C9 by Ritonavir or Nelfinavir. Drug metabolism and disposition: the biological fate of chemicals. 2011. Kirby Brian J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy. The Indian journal of medical research. 2011. Lakhan Ram, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast cancer research and treatment. 2011. Lu Wenjie Jessie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clinical pharmacology and therapeutics. 2011. Simon T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. European heart journal. 2011. van Schie Rianne M F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. European journal of clinical pharmacology. 2011. Choi Chang-Ik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide. The breast journal. 2011. Wessels Alette M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood. 2011. Gong Inna Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. Journal of the American Medical Informatics Association : JAMIA. 2011. Xu Hua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics. 2011. Patterson Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Annals of hematology. 2011. Gan Gin Gin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical pharmacology and therapeutics. 2011. Scott S A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. European journal of clinical pharmacology. 2011. Zhong Shi-Long, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics. 2011. Sehrt Daniel, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. 2011. Mitchell Cathrine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. British journal of clinical pharmacology. 2011. Lim Joanne S L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. Clinical pharmacology and therapeutics. 2011. Mürdter T E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. The pharmacogenomics journal. 2011. Do E J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation. Arquivos de neuro-psiquiatria. 2011. Twardowschy Carlos Alexandre, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. European journal of clinical pharmacology. 2011. Geisen Christof, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. Journal of human genetics. 2011. Choi Jung Ran, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The missing association: sequencing-based discovery of NOVEL SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clinical pharmacology and therapeutics. 2011. Perera M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomics and drug response. The New England journal of medicine. 2011. Wang Liewei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Optimization of warfarin dose by population-specific pharmacogenomic algorithm. The pharmacogenomics journal. 2011. Pavani A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. The pharmacogenomics journal. 2011. Chan S L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomics of warfarin dose requirements in Hispanics. Blood cells, molecules & diseases. 2011. Cavallari Larisa H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. European journal of clinical pharmacology. 2011. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. European journal of neurology : the official journal of the European Federation of Neurological Societies. 2011. Depondt C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Global patterns of genetic diversity and signals of natural selection for human ADME genes. Human molecular genetics. 2011. Li Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic warfarin dosing tables versus algorithms. Journal of the American College of Cardiology. 2011. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. Journal of thrombosis and thrombolysis. 2011. You Joyce H S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenetics and genomics. 2011. Teichert Martina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients. Pharmacogenetics and genomics. 2011. Shahin Mohamed Hossam A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics. 2011. Shin Jaekyu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thrombosis and haemostasis. 2011. Luxembourg Baete, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease. Annals of clinical and laboratory science. 2011. Moon Hee-Won, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010. Nowak-Göttl Ulrike, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European heart journal. 2010. Harmsze Ankie M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. European journal of clinical pharmacology. 2010. Pedersen Rasmus S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Human molecular genetics. 2010. Cha Pei-Chieng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmacogenomics and personalized medicine. 2011. Lucire Yolande, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation. PloS one. 2011. Gong Inna Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. The pharmacogenomics journal. 2010. Suarez-Kurtz G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients. Therapeutic drug monitoring. 2010. Ramasamy Kesavan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
[Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2011. Yamamoto Yoshiaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics. 2010. Swen Jesse J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. The Journal of molecular diagnostics : JMD. 2010. Pratt Victoria M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials. 2010. French Benjamin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics. 2010. Haschke-Becher Elisabeth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicology mechanisms and methods. 2010. Amini-Shirazi Noushin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clinical pharmacology and therapeutics. 2010. Rosenborg S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expectations, validity, and reality in pharmacogenetics. Journal of clinical epidemiology. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. Journal of human genetics. 2010. Ross Kendra A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients. British journal of clinical pharmacology. 2010. Lee Su-Jun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. British journal of clinical pharmacology. 2010. Cen Han-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clinical pharmacology and therapeutics. 2010. Karonen T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. European journal of clinical pharmacology. 2010. Kesavan Ramasamy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clopidogrel pathway. Pharmacogenetics and genomics. 2010. Sangkuhl Katrin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenetics and genomics. 2010. Sagreiya Hersh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clinical pharmacology and therapeutics. 2010. Hamberg A-K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin. Clinical pharmacology and therapeutics. 2010. Carbonell N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. European journal of clinical pharmacology. 2010. Puehringer Helene, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). Journal of the American College of Cardiology. 2010. Epstein Robert S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalized therapy in pain management: where do we stand?. Pharmacogenomics. 2010. Stamer Ulrike M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Changes in the gene expression profile of gastric cancer cells in response to ibuprofen: a gene pathway analysis. The pharmacogenomics journal. 2010. Bonelli P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Therapeutic drug monitoring. 2010. McMillin Gwendolyn A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thrombosis research. 2010. Wells P S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharmaceutics & drug disposition. 2010. Zhou Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circulation journal : official journal of the Japanese Circulation Society. 2010. Takeuchi Fumihiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clinical neurology and neurosurgery. 2010. Tan Lan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A Phenotype-Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clinical pharmacology and therapeutics. 2010. Dumond J B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clinical pharmacology and therapeutics. 2010. Lenzini P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug metabolism and disposition: the biological fate of chemicals. 2010. Kazui Miho, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. European journal of clinical pharmacology. 2010. Molden Espen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Journal of clinical pharmacology. 2010. Farid Nagy A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of thrombosis and haemostasis : JTH. 2010. Lubitz S A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and genomics. 2010. Harmsze Ankie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Voora D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Cavallari L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Cavallari L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and genomics. 2010. Van Booven Derek, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
New insights into the regulation of CYP2C9 gene expression: the role of the transcription factor GATA-4. Drug metabolism and disposition: the biological fate of chemicals. 2010. Mwinyi Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. European journal of clinical pharmacology. 2010. Cadamuro Janne, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart and vessels. 2010. Ozer Nihat, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. The Journal of pharmacology and experimental therapeutics. 2010. Chaudhry Amarjit S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The pharmacogenomics journal. 2010. Edvardsen H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clinical pharmacology and therapeutics. 2010. Pautas E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clinical pharmacology and therapeutics. 2010. Zhou K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of thrombosis and haemostasis : JTH. 2010. Ferder N S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics. 2010. Zambon Carlo-Federico, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochemical pharmacology. 2009. Zharikova Olga L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR. 2010. Gor Priya P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug metabolism and pharmacokinetics. 2010. Uchida Shinya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions. Drug metabolism and pharmacokinetics. 2010. Zi Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. European journal of clinical pharmacology. 2009. Jiang Dechun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. Journal of clinical pharmacology. 2009. Hennessy Sean, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics. 2009. Lee M T Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: role in medicines approval and clinical use. Public health genomics. 2010. Novelli G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. European journal of clinical pharmacology. 2009. Ohno Masako, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009. Ragia Georgia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clinical chemistry. 2009. Linder Mark W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A genome-wide association study of acenocoumarol maintenance dosage. Human molecular genetics. 2009. Teichert Martina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenetics and genomics. 2009. Jorgensen Andrea L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenetics and genomics. 2009. Salinger David H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics. 2009. van Schie Rianne M F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. The pharmacogenomics journal. 2009. Kaur-Knudsen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prevalence of CYP2C9 polymorphisms in the south of Europe. The pharmacogenomics journal. 2009. Sánchez-Diz Paula, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica; the fate of foreign compounds in biological systems. 2009. Li Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug metabolism and disposition: the biological fate of chemicals. 2009. Maekawa Keiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. European journal of clinical pharmacology. 2009. Joy Melanie S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics in cardiovascular antithrombotic therapy. Journal of the American College of Cardiology. 2009. Marín Francisco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics. 2009. Janha Ramatoulie E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics. 2009. Oliveira Elisabete, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Generating genome-scale candidate gene lists for pharmacogenomics. Clinical pharmacology and therapeutics. 2009. Hansen N T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. European journal of clinical pharmacology. 2009. Fuchshuber-Moraes Mateus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. European journal of clinical pharmacology. 2009. Werner D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. Journal of thrombosis and thrombolysis. 2009. Qazim Berisha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Global variation in CYP2C8-CYP2C9 functional haplotypes. The pharmacogenomics journal. 2009. Speed William C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinically available pharmacogenomics tests. Clinical pharmacology and therapeutics. 2009. Flockhart D A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available